Cargando…
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
PURPOSE OF REVIEW: Since the discovery of PCSK9 in 2003, this proprotein convertase was shown to target specific receptors for degradation in endosomes/lysosomes, including LDLR and other family members and hence to enhance the levels of circulating LDL-cholesterol (LDLc). Accordingly, inhibitors of...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335453/ https://www.ncbi.nlm.nih.gov/pubmed/35904732 http://dx.doi.org/10.1007/s11883-022-01057-z |
_version_ | 1784759344503455744 |
---|---|
author | Seidah, Nabil G. Garçon, Damien |
author_facet | Seidah, Nabil G. Garçon, Damien |
author_sort | Seidah, Nabil G. |
collection | PubMed |
description | PURPOSE OF REVIEW: Since the discovery of PCSK9 in 2003, this proprotein convertase was shown to target specific receptors for degradation in endosomes/lysosomes, including LDLR and other family members and hence to enhance the levels of circulating LDL-cholesterol (LDLc). Accordingly, inhibitors of PCSK9, including monoclonal antibodies blocking its circulating activity and siRNA silencers of its hepatic expression, are now used in clinics worldwide to treat hypercholesterolemia patients effectively and safely in combination with statins and/or ezetimibe. These powerful treatments reduce the incidence of atherosclerosis by at least 20%. Since 2008, novel targets of PCSK9 began to be defined, thereby expanding its roles beyond LDLc regulation into the realm of inflammation, pathogen infections and cellular proliferation in various cancers and associated metastases. RECENT FINDINGS: Some pathogens such as dengue virus exploit the ability of PCSK9 to target the LDLR for degradation to enhance their ability to infect cells. Aside from increasing the degradation of the LDLR and its family members VLDLR, ApoER2 and LRP1, circulating PCSK9 also reduces the levels of other receptors such as CD36 (implicated in fatty acid uptake), oxidized LDLR receptor (that clears oxidized LDLc) as well as major histocompatibility class-I (MHC-I) receptors (implicated in the immune response to antigens). Thus, these novel targets provided links between PCSK9 and inflammation/atherosclerosis, viral infections and cancer/metastasis. The functional activities of PCSK9, accelerated the development of novel therapies to inhibit PCSK9 functions, including small molecular inhibitors, long-term vaccines, and possibly CRISPR-based silencing of hepatic expression of PCSK9. SUMMARY: The future of inhibitors/silencers of PCSK9 function or expression looks bright, as these are expected to provide a modern armamentarium to treat various pathologies beyond hypercholesterolemia and its effects on atherosclerosis. |
format | Online Article Text |
id | pubmed-9335453 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-93354532022-07-29 Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond Seidah, Nabil G. Garçon, Damien Curr Atheroscler Rep Genetics and Genomics (R.A. Hegele and L. Brunham, Section Editors) PURPOSE OF REVIEW: Since the discovery of PCSK9 in 2003, this proprotein convertase was shown to target specific receptors for degradation in endosomes/lysosomes, including LDLR and other family members and hence to enhance the levels of circulating LDL-cholesterol (LDLc). Accordingly, inhibitors of PCSK9, including monoclonal antibodies blocking its circulating activity and siRNA silencers of its hepatic expression, are now used in clinics worldwide to treat hypercholesterolemia patients effectively and safely in combination with statins and/or ezetimibe. These powerful treatments reduce the incidence of atherosclerosis by at least 20%. Since 2008, novel targets of PCSK9 began to be defined, thereby expanding its roles beyond LDLc regulation into the realm of inflammation, pathogen infections and cellular proliferation in various cancers and associated metastases. RECENT FINDINGS: Some pathogens such as dengue virus exploit the ability of PCSK9 to target the LDLR for degradation to enhance their ability to infect cells. Aside from increasing the degradation of the LDLR and its family members VLDLR, ApoER2 and LRP1, circulating PCSK9 also reduces the levels of other receptors such as CD36 (implicated in fatty acid uptake), oxidized LDLR receptor (that clears oxidized LDLc) as well as major histocompatibility class-I (MHC-I) receptors (implicated in the immune response to antigens). Thus, these novel targets provided links between PCSK9 and inflammation/atherosclerosis, viral infections and cancer/metastasis. The functional activities of PCSK9, accelerated the development of novel therapies to inhibit PCSK9 functions, including small molecular inhibitors, long-term vaccines, and possibly CRISPR-based silencing of hepatic expression of PCSK9. SUMMARY: The future of inhibitors/silencers of PCSK9 function or expression looks bright, as these are expected to provide a modern armamentarium to treat various pathologies beyond hypercholesterolemia and its effects on atherosclerosis. Springer US 2022-07-29 2022 /pmc/articles/PMC9335453/ /pubmed/35904732 http://dx.doi.org/10.1007/s11883-022-01057-z Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Genetics and Genomics (R.A. Hegele and L. Brunham, Section Editors) Seidah, Nabil G. Garçon, Damien Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond |
title | Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond |
title_full | Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond |
title_fullStr | Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond |
title_full_unstemmed | Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond |
title_short | Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond |
title_sort | expanding biology of pcsk9: roles in atherosclerosis and beyond |
topic | Genetics and Genomics (R.A. Hegele and L. Brunham, Section Editors) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335453/ https://www.ncbi.nlm.nih.gov/pubmed/35904732 http://dx.doi.org/10.1007/s11883-022-01057-z |
work_keys_str_mv | AT seidahnabilg expandingbiologyofpcsk9rolesinatherosclerosisandbeyond AT garcondamien expandingbiologyofpcsk9rolesinatherosclerosisandbeyond |